

UNAUDITED FINANCIAL RESULTS [PROVISIONAL] OF QUARTER ENDED 30TH JUNE, 2008

(Rs. in Lacs)

Particulars	Quarter Ended 30.06.2008 (Unaudited)	Quarter Ended 30.06.2007 (Unaudited)	12 Months Ended 31.03.2008 (Unaudited)
1. Net Sales/Income from operations	2212.15	2406.73	11241.66
2. Other Income	55.38	95.05	348.67
3. Total Expenditure			
(a) (Increase)/Decrease in Stock in Trade	(215.51)	(58.09)	88.17
(b) Consumption of Materials	1398.98	1297.10	6438.34
(c) Staff Cost	199.06	164.79	733.95
(d) Other Expenditure (Incl. Excise Duty)	524.82	694.24	2811.72
	1907.35	2098.04	10072.18
4. Operational Profit/(Loss) before Interest, Depreciation and Taxation	360.18	403.74	1518.15
5. Interest & Finance Cost	170.72	189.41	691.81
6. Depreciation	37.72	39.35	178.48
7. Profit/(Loss) before Tax (4-5-6)	151.74	174.98	647.86
8. Exchange Rate Fluctuation	0.00	0.00	169.80
9. Earlier Year Taxes	-	-	(1.05)
Provision for Tax (FBT)	4.00	3.00	15.00
10. Net Profit / (Loss) (7-8-9)	147.74	171.98	464.11
11. Paid-up Equity Share Capital (Face Value Rs.10/- per Share)	2158.00	1527.50	2093.00
Paid up Pref. Share Capital (Face Value Rs. 100/- per Share)	108.57	108.57	108.57
12. Reserves excluding Revaluation Reserve	-	-	5,693.36
13. Earning Per Share (Basic & Diluted)	0.71	1.12	1.93
14. Aggregate of Non-promoter Share-holding			
Number of Shares	16,552,735	11,892,785	16,552,735
Percentage of Shareholding	76.70	77.86	79.09

Notes:

- The above results, were duly considered by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on 31st July, 2008.
- The Company has one Single Segment "Pharmaceuticals".
- Net sales/Income from operations include Processing & Development Charges of Rs.21.71 Lacs.
- The loss/gain on exchange fluctuation on GDR Funds for the current year will be provided at the end of the year.
- During the quarter Company allotted 650000 Equity Shares of Rs.10/- each on conversion of 650000 Equity Warrants at an exercise price of Rs.41.50 per warrant.
- No complaint of Investors received during the quarter.
- Audit qualifications in respect of Audited Accounts for 2005-07 and management comments thereon are detailed below:
 - The deferment of R&D expenditure of Rs.1,67,14,878/- & GDR Issue expenses of Rs.91,61,542/- which is not in compliance with Accounting Standard (AS-26). The Company has explained at note No. 15 to the accounts.
 - Regarding non-provision of arrears of ex-gratia at Rs.3,66,69,307/-, the matter presently is subjudice.

For LYKA LABS LIMITED

(N. I. GANDHI)

Chairman & Managing Director

Place : Mumbai

Dated: 31st July, 2008